Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) hit a new 52-week low on Thursday.

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN®

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.12) per share which missed the analy

Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf

In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy

DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first

Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintain

Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.11) per share which beat the analyst

DBV Tech (DBVT) maintains progress with BLA submission for VIASKIN peanut patch in children. Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analy

Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf

Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintain

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.23) per share which beat the analyst

Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings an

Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings an

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Pa

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped highe